Anti-Mouse CD209b [Clone 22D1] — Purified in vivo GOLD™ Functional Grade

Clone 22D1 is primarily used in vivo in mice to target CD209b (SIGN-R1), a receptor expressed on certain macrophages involved in innate immunity.

Key in vivo applications include:

• Temporary Knockdown of SIGN-R1 Expression: Injection of clone 22D1 in mice leads to a transient reduction in SIGN-R1 levels, allowing researchers to study the role of this receptor in immune processes, especially its function in pathogen recognition and clearance.
• Attenuation of Allergic Airway Inflammation: In vivo neutralization of CD209b using clone 22D1 can reduce allergic responses in mouse models, facilitating investigation into mechanisms of inflammation and potential therapeutic targets.
• Functional Immune Response Studies: By blocking or modulating CD209b, clone 22D1 is used to probe macrophage-mediated uptake of pathogen-associated molecules such as lipopolysaccharides and polysaccharides, informing models of host-pathogen interaction.
• Modeling Marginal Zone Macrophage Function: The antibody is frequently used to study the role of CD209b-expressing macrophages in the spleen marginal zone and lymph node medulla, which are key sites for innate immune surveillance.
• Validation in Flow Cytometry, Immunohistochemistry (IHC), and ELISA: Although these are often ex vivo, in vivo administration is sometimes followed by cell/tissue analysis with 22D1 to confirm receptor modulation and immune cell distribution.

Summary of Typical Use Case Workflow:

• Mice are administered clone 22D1 antibody, typically via intravenous or intraperitoneal injection.
• This results in either a functional blockade or depletion/knockdown of CD209b/SIGN-R1.
• Researchers then analyze downstream effects on immune cell behavior, uptake of pathogens, or inflammatory response, often using flow cytometry, IHC, or ELISA.

Clone 22D1 is a specific tool for dissecting the function of SIGN-R1 in murine models, particularly in the context of innate immunity, macrophage biology, and inflammatory disease.

In the literature, the 22D1 antibody is commonly used to target mouse CD209b (SIGN-R1), a receptor involved in the innate immune response. While specific studies combining 22D1 with other antibodies might vary, here are some general examples of antibodies or proteins that are often used in immunological research:

1. PD-L1 antibodies (e.g., SP263, SP142, 28-8, 22C3): These are used in immunohistochemistry assays to assess PD-L1 expression, which is relevant in cancer research and immunotherapy.

2. TSC22D1 antibodies: These target TSC22D1, a protein involved in transcription regulation. TSC22D1 antibodies are used in various applications like Western blot, immunoprecipitation, and immunohistochemistry.

3. General Flow Cytometry Antibodies: In studies involving flow cytometric analysis, antibodies targeting other immune cell markers (e.g., CD3, CD4, CD8, CD19) are commonly used alongside the 22D1 antibody to analyze cell populations in the immune system.

4. Recombinant Protein-based Reagents: These might include proteins like recombinant mouse CD209b, used as immunogens or in functional assays to study the role of CD209b in immune responses.

The choice of antibodies or proteins used in conjunction with 22D1 typically depends on the specific research question, such as studying immune cell interactions, pathogen recognition, or the role of CD209b in disease models.

Based on the available information, the key findings from clone 22D1 citations relate to anti-mouse CD209b monoclonal antibody research, specifically in the context of bacterial infection studies.

Therapeutic Efficacy in Bacterial Infections

The most significant finding demonstrates that 22D1 treatment showed substantial therapeutic benefits in experimental bacterial infection models. Treatment with this antibody increased the survival rate to 70% in infected subjects. Additionally, bacterial loads in blood were dramatically reduced by 2 logs (approximately 100-fold reduction), indicating strong antimicrobial efficacy.

Antibody Characteristics

Clone 22D1 is characterized as recognizing an epitope on mouse CD209b, a single-pass type II membrane protein with a molecular weight of 37 kD. This antibody has been developed and is commercially available through multiple suppliers for in vivo functional studies, including purified formats designated as GOLD™ and PLATINUM™ functional grades.

The CD209b target itself plays a role in immune recognition and response, making this antibody clone valuable for studying immune-mediated mechanisms during bacterial infections and potentially for therapeutic interventions targeting pathogen clearance.

Dosing Regimen Variability for Clone 22D1 in Mouse Models

Current Evidence on Clone 22D1 Dosing

No available search results specifically detail dosing regimens for clone 22D1 (anti-mouse CD209b) across different mouse tumor models or experimental contexts. Most results provide detailed dosing guidelines for well-characterized immune checkpoint antibodies (e.g., RMP1-14, 10F.9G2, 9D9, 29F.1A12), but these do not include clone 22D1.

General Principles for In Vivo Dosing in Mice

Although clone 22D1 data are absent, general principles and common practices in mouse oncology and immunology studies can be inferred:

• Dose Range: For most monoclonal antibodies in cancer immunotherapy, typical in vivo doses in mice range from 100 to 500 µg per mouse, administered via intraperitoneal injection, though this can vary by antibody and model.
• Dosing Schedule: Antibodies are often given every 2–4 days, with schedules adapted based on pharmacokinetics (PK), pharmacodynamics (PD), and observed efficacy/toxicity.
• Model-Specific Adjustments: Dosing can vary depending on tumor type, mouse strain, and experimental endpoints (e.g., tumor growth inhibition, immune cell profiling).
• Empirical Testing: New clones or less-studied antibodies like 22D1 typically require empirical titration to establish a tolerated and effective dose in each model, guided by pilot studies and literature on similar agents.

Why Data on Clone 22D1 May Be Limited

Clone 22D1 targets mouse CD209b (SIGNR4), a receptor involved in immune regulation, but is not as widely used in standard immunotherapy protocols as anti-PD-1 or anti-CTLA-4 antibodies. This likely explains the absence of published dosing guidelines in the current literature summarized in the search results. Researchers using 22D1 should consult the supplier’s technical data sheet, preprint servers, or direct literature searches for model-specific data.

Recommendations

• Consult Vendor Documentation: Suppliers such as Leinco may provide suggested starting doses for clone 22D1 in their product sheets.
• Conduct Pilot Studies: If no published data exist, perform dose-finding studies in the intended mouse model, starting within the typical antibody dose range (e.g., 100–250 µg per mouse) and adjusting based on tolerability and efficacy.
• Monitor for Toxicity: Especially in combination therapies, closely monitor for adverse effects, as dosing regimens can be model- and combination-dependent.
• Optimize Schedule: Consider weekly or biweekly dosing initially, then refine based on pharmacodynamic (PD) and pharmacokinetic (PK) data, if available.

Summary Table: Typical Antibody Dosing in Mice (for Reference)

Conclusion

There is no published evidence in the provided search results specifying how dosing regimens for clone 22D1 vary across different mouse models. Users should follow general antibody dosing principles in mice, consult product-specific documentation, and perform pilot experiments to define optimal and model-appropriate dosing for clone 22D1.